Fascin inhibition has been reported to increase intratumoral dendritic cell activation and anti-cancer immunity [49], and these findings suggest possible influences of FRA1 on anti-tumor immunity that warrant further investigation in immune-competent models. The gene discussed is FSCN1; the disease is cancer.